

IMMUNOTHERAPY BRIDGE
30 novembre - 1 dicembre 2026
Napoli, Royal Continental Hotel (Via Partenope 38)

Responsabile Scientifico

Paolo A. Ascierto | Professore Ordinario di Oncologia, Università Federico II, Napoli; Direttore Struttura Complessa Oncologia Sperimentale, Melanoma, Immunoterapia e Terapie Innovative, Istituto Nazionale dei Tumori IRCCS Fondazione G. Pascale, Napoli

Congresso ECM

Destinatari dell'attività formativa:

Farmacista (Farmacista pubblico del SSN); **Medico Chirurgo** (Allergologia ed immunologia clinica; dermatologia e venereologia; ematologia; gastroenterologia; Malattie dell'apparato respiratorio; medicina interna; nefrologia; neurologia; oncologia; radioterapia; chirurgia generale; chirurgia plastica e ricostruttiva; ginecologia e ostetricia; urologia; anatomia patologica; farmacologia e tossicologia clinica; laboratorio di genetica medica; medicina nucleare; patologia clinica (laboratorio di analisi chimico-cliniche e microbiologia); radiodiagnostica; igiene, epidemiologia e sanità pubblica; medicina generale (medici di famiglia); Scienza dell'alimentazione e dietetica; cure palliative);

Numero partecipanti: 201 discenti

Quota di iscrizione: 880,00 euro è IVA 22% (include partecipazione ai lavori congressuali, breaks come da programma, congress bags)

Quota di iscrizione ridotta SOCI AIOM: 600,00 euro + IVA 22%

n. 5 iscrizioni gratuite SOCI AIOM

RAZIONALE SCIENTIFICO

Over the last years, an extensive research has improved our understanding of tumor immunology and enabled the development of novel treatments that can harness the patient's immune system and prevent immune escape.

Through numerous clinical trials and real-world experience, a large amount of evidence of the potential for long-term survival with immunotherapy agents has been accumulated in various types of malignancy, starting from melanoma to extend to other tumors.

The results of these studies have also highlighted a number of recurring observations with immuno-oncology agents, including their potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The clinical success of immune checkpoint blockade with anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and anti-programmed death (PD)-1/PD-ligand (L)1 inhibitor in melanoma and other cancers has encouraged increasing development of other immunotherapies, particularly monoclonal antibodies with other immune targets, adoptive cell transfer and vaccines. It has been estimated that

there are over 3000 immuno-oncology trials ongoing, targeting hundreds of disease and immune pathways. Study results have highlighted a number of recurring observations, including the immunotherapy potential for clinical application across a broad patient population and for both conventional and unconventional response patterns.

The successes of the immune-oncology is strongly correlated with the immune system ability of “memory” and adaptability, to improve the time of survival and without selecting resistant form of tumoral cells. Another advantage is that the efficacy of immunotherapy drugs does not seem to be particularly influenced by histology and mutations.

The Immunotherapy Bridge will start with a Session jointly organized with SITC on modulator of Tumor Immunity and Immunotherapy.

Hence, we will discuss the state of the art of immunotherapy, novel drug development and novel approaches to cancer therapy, the last update on cancer vaccines and AI and then the organ specific immune response to share what different cancers teach about the general understanding of malignancies.

The final session will be focused on neoadjuvant therapies across cancers.

Immunotherapy Bridge will end with the Great Debate Sessions, in which the most important issues from clinical practice and research will be shown and exhaustively discussed from two different points of view.

PROGRAMMA SCIENTIFICO

**Speakers to be confirmed*

***NOT CME accreditation*

DAY 1

Monday, Nov 30th

10.00 AM Introduction and Objectives, *Paolo A. Ascierto*

SITC SESSION - Modulator of Tumor Immunity and Immunotherapy

Chairpersons: James L. Gulley, Igor Puzanov

10.10 AM Barriers to CAR T cells effectiveness, *Marco Ruella*

10.25 AM Q&A

10.30 AM Microbiome update, *Laurence Zitvogel**

10.45 AM Q&A

10.50 AM Systemic vs Local Metabolism, *Greg Delgoffe*

11.05 AM Q&A

11.10 AM Effects of aging and Immunity, *Leisha A. Emens**

11.25 AM Q&A

11.30 AM Nerves and Immune Cells, *Christine Moussion*

11.45 AM Q&A

11.50 AM The best of SITC 2026. *Paolo A. Ascierto*

12.10 AM Q&A

12.15 PM LECTURE

12.45 PM Lunch**

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Bernard A. Fox, James L. Gulley, Igor Puzanov

1.45 PM Fecal Transfer vs Diet, *Laurence Zitvogel* VS Jennifer McQuade*

2.10 PM GLP1 is just weight loss: yes or no, *Jennifer Wargo* VS Janis Taube**

SESSION 2 - NOVEL DRUG DEVELOPMENT and NOVEL APPROACHES TO CANCER THERAPY

Chairpersons: *Alfredo Budillon, Luigi Buonaguro**

2.35 PM Bispecific Antibodies, *James L. Gulley*

2.50 PM ADCs: Novel targets and novel payloads, *Leisha A. Emens**

3.10 PM NK Cells, *Andreas Lundqvist*

3.25 PM Radio Ligands, *Charles Manning**

3.40 PM Cytokines, *Howard Kaufman*

3.55 PM Radiation as immunomodulating modality, *Sandra Demaria*

4.10 PM Discussion

4.35 PM Coffee Break**

SESSION 3 – CANCER VACCINES AND AI

Chairpersons: *Bernard A. Fox, Catherine Wu**

4.45 PM The Dark Matter, *Bernard A. Fox*

5.00 PM mRNA Vaccines, *Paolo A. Ascierto*

5.15 PM Peptide Vaccines, *Catherine Wu**

5.30 PM US NCI national roadmap for cancer vaccines, *Stacey Adams**

5.45 PM Shared Antigens, *Olivera Finn**

6.00 PM AI, *Carlo Bifulco**

6.15 PM DISCUSSION

DAY 2

Tuesday, Dec 1st

SESSION 4 - ORGAN SPECIFIC IMMUNE RESPONSE

Chairperson: *Omid Hamid*

9.15 AM Pancreatic Cancer, *Gregory Lesinski*

9.30 AM Colon Cancer, *Myriam Chalabi**

9.45 AM RCC, *Toni Choueiri*

10.00 AM Bladder, *Andrea Necchi**

10.15 AM Brain, *Hussein Tawbi*

10.30 AM Ovarian, *Kunle Odunsi**

10.45 AM Prostate, *Matthew Dallos**

11.00 AM Head & Neck, *Robert Ferris**

11.15 AM DISCUSSION

11.30 AM Coffee Break**

GREAT DEBATE

Chairpersons: Paolo A. Ascierto, Bernard A. Fox, James L. Gulley, Igor Puzanov

11.45 AM Models: pro/cons of animal vs human, *Stefani Spranger* vs Bernard Fox*

12.10 PM CD4 vs CD8 Effector Cells, *Larry Fong* VS Pedro Romero*

12.35 PM Macrophages vs CAF, *Mikael Pittet* VS Fatima Machta Grigoriou*

1.00 PM Lunch**

2.00 PM SYMPOSIUM – Non-Melanoma Skin Cancers

The treatment of CSCC and BCC: an update

*Paolo A. Ascierto, Dirk Schadendorf**

SESSION 5 - NEOADJUVANT THERAPY ACROSS CANCERS

Chairpersons: Paolo A. Ascierto, Elizabeth M. Burton

2.50 PM INNOVATE summary, *Paolo A. Ascierto*

3.05 PM Breast, *Marlene Kok*

3.20 PM Lung, *Tina Cascone*

3.35 PM Melanoma, *Christian Blank**

3.50 PM Non-Melanoma Skin Cancers, BCC and CSCC, *Neil D. Gross**

4.05 PM Histology agnostic neoadjuvant trials, *Myriam Chalabi**

4.20 PM Pan-tumor path response assessment, *Julie Stein Deutsch**

4.35 PM DISCUSSION

5.00 PM **Conclusion**, *Paolo A. Ascierto, Bernard A. Fox, James Gulley, Igor Puzanov*